玻璃体腔注射雷珠单抗联合小梁切除术治疗新生血管性青光眼疗效观察

目的观察玻璃体腔注射雷珠单抗（Lucentis）联合复合式小梁切除术治疗新生血管性青光眼的疗效。方法对17例（17只眼）新生血管性青光眼行玻璃体腔注射Lucentis 0.50 mg/0.05 ml,8~14 d后行复合式小梁切除术。观察玻璃体腔注射Lucentis后虹膜及房角新生血管消退的时间、眼压的变化以及复合式小梁切除术后视力和眼压的变化。术后随访8~12个月。结果玻璃体腔注射Lucentis后,13只眼虹膜新生血管1周内完全消退,4只眼2二周内完全消退。注药前平均眼压（39.56±10.12）mm Hg,注药后1周平均眼压（38.62±8.35）mm Hg与注药前比较眼压变化无统计学意义（t=0.951,P〉0.05）。小梁切除术后1周眼压（10.43±6.12）mm Hg,最后一次随访眼压（13.61±4.31）mm Hg,与术前比较差异均有统计学意义（t=21.362、19.817,P均﹤0.01）。末次随访时12只眼视力提高,5只眼视力未变。结论玻璃体腔注射雷珠单抗联合复合式小梁切除术能有效地控制眼压,保护视功能。     

新生血管性青光眼手术探讨

目的 比较全视网膜冷凝术（ＰＲＣ）联合小梁切除,自体巩膜条引流术与前视网膜冷凝术（ＡＲＣ）联合小梁切除术对新生血管性青光眼的疗效。方法 ４２例随机分成Ａ,Ｂ两组,分别行ＡＲＣ联合小梁切除术和ＰＲＣ联合小梁切除,自体巩膜条引流术。结果 术后第１天,Ｂ组眼压明显高于Ａ组,而术后末期随访Ｂ组眼压下降及虹膜新生血管消退均优于Ａ组。     

视网膜及虹膜光凝联合小梁切除术治疗新生血管性青光眼

目的 观察视网膜及虹膜光凝联合小梁切除术治疗新生血管性青光眼的效果.方法 对32例(34只眼)新生血管性青光眼先行全视网膜光凝,再行虹膜光凝,用氪-绿激光封闭虹膜表面及房角新生血管,3～5d后行复合式小梁切除术,观察手术前后的最佳矫正视力、眼压、使用抗青光眼药物的数量,虹膜新生血管消退情况及术中术后并发症等.结果 治疗后视力提高14只眼,无变化14只眼,下降6只眼;在用抗青光眼药物的情况下,治疗前眼压平均(42.9±8.9)mmHg,术后1周、1月及3月平均眼压为(13.6±3.4)mmHg,(15.4±3.0)mmHg,及(18.2 4±3.1)mmHg(t值分别为t=17.695.t=18.669,t=14.781,均P<0.05)治疗前后对比有统计学意义.抗青光眼用药量从治疗前3.1±0.8降至治疗后0.2±0.6(t=15.760.P=0.000<0.05)治疗前后对比有统计学意义.术后并发症:术后早期前房出血5只眼(14.7%),经药物治疗均在2周内消失;1只眼术后2月发生睫状环阻滞性青光眼,药物治疗后缓解.结论 采用视网膜及虹膜光凝联合小梁切除术,治疗新生血管性青光眼能有效降低新生血管性青光眼患者眼压及减少术中、术后并发症,为新生血管性青光眼治疗提供了一种经济有效的综合治疗方法.     

复合式小梁切除术联合睫状体冷凝治疗晚期新生血管性青光眼

目的探讨复合式小梁切除术联合睫状体冷凝治疗晚期新生血管性青光眼的疗效。方法晚期新生血管性青光眼16例（16眼）．一次性施行180°睫状体冷凝联合复合式小梁切除术．观察术后眼压、新生血管消退情况及手术并发症。结果术后随访6—48个月,视力均无明显改善,平均眼压自（57．48±10．00）mmHg降至（12．46±4．36）mmHg,控制在21mmHg以下者13眼（占80．12％）,手术眼压控制较好。结论一次性施行复合式小梁切除术联合睫状体冷凝对晚期新生血管性青光眼有较好的长期疗效。     

Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab

Aims

To compare the outcomes of neovascular glaucoma (NVG) treated with and without intravitreal bevacizumab in a large case comparison study.

Methods

The study is a retrospective, comparative, case series of 163 eyes of 151 patients with NVG, including 99 treated without and 64 treated with intravitreal bevacizumab. Medical and surgical treatments for NVG were assessed. The main outcome measures were visual acuity (VA) and intraocular pressure (IOP).

Results

At the time of NVG diagnosis, the median VA was count fingers (CF) in the non-bevacizumab group and 2/300 in the bevacizumab group. IOP (mean±SD) was 43.1±13.0 mm Hg in the non-bevacizumab group and 40.8±11.5 mm Hg in the bevacizumab group. IOP (mean±SD) decreased to 18.3±13.8 mm Hg in the non-bevacizumab group and 15.3±8.0 mm Hg in the bevacizumab group, and the median VA was CF in both treatment groups at a mean follow-up of 12 months. Panretinal photocoagulation (PRP) substantially reduced the need for glaucoma surgery (P<0.001) in bevacizumab treated NVG eyes.

Conclusions

Although bevacizumab delayed the need for glaucoma surgery, PRP was the most important factor that reduced the need for surgery. Vision and IOP in eyes with NVG treated with bevacizumab showed no long-term differences when compared with eyes that were not treated with bevacizumab. Thus, intravitreal bevacizumab serves as an effective temporizing treatment, but is not a replacement for close monitoring and definitive treatment of NVG. PRP remains the treatment modality that affects the course of NVG in terms of decreasing the need for surgery to control IOP.     

尿毒症血液透析继发新生血管性青光眼的治疗

目的评价睫状体冷凝联合小梁切除术治疗尿毒症血液透析后继发新生血管性青光眼(neovascular glaucoma,NVG)的临床效果。方法对10例(13眼)尿毒症血液透析后继发NVG的患者的临床资料进行回顾性分析。所有患者均行睫状体冷凝及小梁切除术,观察术后前房反应、房角及虹膜新生血管、眼压、视力及并发症等。术后随访12～18个月。结果术后13眼视力均无明显变化。出现一过性高眼压5眼,前房积血4眼,前部葡萄膜炎4眼,经对症处理后均于1～2周恢复。3眼术前房角新生血管均完全消失;虹膜新生血管完全消失者7眼,减少者1眼,2眼保持不变或增多者于术后1个月后再次给予睫状体冷凝治疗后新生血管消失。11眼眼压均得以控制,2眼术后给予药物治疗后眼压得以控制。末次随访时,除1例患者因肾脏移植术后合并感染死亡外,其余9例患者均能继续维持血液透析,均未再出现眼压增高。结论血液透析时多重因素诱发视网膜微循环障碍是引起NVG发生的主要原因,睫状体冷凝联合小梁切除术能够有效治疗尿毒症血液透析后NVG。     

Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma

AIM: To evaluate the efficacy and safety of intravitreal ranibizumab (IVR) with panretinal photocoagulation (PRP) followed by trabeculectomy compared with Ahmed glaucoma valve (AGV) implantation in neovascular glaucoma (NVG). METHODS: This was a retrospective comparative study. We reviewed the cases of a total of 45 eyes from 45 NVG patients among which 23 eyes underwent AGV implantation and the other 22 underwent trabeculectomy. The causes of neovascular glaucoma included: diabetic retinopathy (25 eyes), and retinal vein occlusion (20 eyes). All patients received preoperative IVR combined with postoperative PRP. The mean best-corrected visual acuities (BCVA) were converted to the logarithms of the minimum angle of resolution (logMAR) for the statisitical analyses. Intraocular pressure (IOP), the logMAR BCVA and surgical complications were evaluated before and after surgery. The follow-up period was 12mo. RESULTS: A total of 39 cases showed complete regression of iris neovascularization at 7d after injection, and 6 cases showed a small amount of residual iris neovascularization. The success rates were 81.8% and 82.6% at 12mo after trabeculectomy and AGV implantation, respectively. In the trabeculectomy group, the logMAR BCVA improved at the last follow-up in 14 eyes, remained stable in 6 eyes and decreased in 2 eyes. In 4 cases, slight hyphemas developed after trabeculectomy. A shallow anterior chamber developed in 2 cases and 2 vitreous hemorrhages. In the AGV group, the logMAR BCVA improved in 14 eyes, remained stable in 5 eyes and decreased in 4 eyes. Slight hyphemas developed in 3 cases, and a shallow anterior chamber in 3 cases. The mean postoperative IOP was significantly lower in both groups after surgery (F=545.468, P<0.05), and the mean postoperative logMAR BCVA was also significantly improved (F=10.964, P<0.05) with no significant difference between two groups. CONCLUSION: It is safe and effective to treat NVG with this combined procedure, and we found similar results after IVR+AGV implantation+PRP and IVR+trabeculectomy+PRP in eyes with NVG.     

Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma

PURPOSE: To determine the outcomes of trabeculectomy with mitomycin C (MMC) combined with direct cauterization of peripheral iris before iridectomy in the management of neovascular glaucoma (NVG), and to demonstrate the effect of this surgical technique on decreasing the incidence of intraoperative bleeding and early postoperative hyphema. METHODS: This prospective study was based on 72 eyes of 72 patients with NVG who underwent primary trabeculectomy with MMC combined with direct cauterization of peripheral iris before iridectomy. The patients were evaluated for intraoperative and early postoperative complications such as hyphema, and operative success rates. Operative success was defined as an intraocular pressure (IOP) < or =22 mm Hg (+/-medical therapy) in the absence of phthisis. The mean IOP and the mean number of antiglaucomatous medications at baseline and at the posttrabeculectomy sixth month were compared by paired Student t test. RESULTS: The mean preoperative IOP was 39.3+/-5.6 mm Hg (range, 29 to 60 mm Hg) whereas it was 20.02+/-4.3 mm Hg (range, 14 to 38 mm Hg) at the postoperative sixth month. The mean preoperative number of antiglaucoma medications was 3.2+/-0.4 (range, 2 to 4) but it reduced to 1.8+/-0.6 (range, 1 to 4) at the postoperative sixth month. These differences were statistically significant (P<0.00001). The IOP was < or =22 mm Hg (+/-medical therapy) in 69 eyes (95.8%) at the postoperative first week, in 62 eyes (86.1%) at the postoperative first month, in 60 eyes (83.3%) at the postoperative third month and in 48 eyes (66%) at the postoperative sixth month. Hyphema occurred in 15 eyes (20.8%) within the first week of the surgery. In 12 eyes it was transient; however, in 3 eyes irrigation of anterior chamber was required. CONCLUSIONS: Trabeculectomy with MMC combined with direct cauterization of peripheral iris decreases the incidence of both intraoperative bleeding, and early postoperative hyphema, and provides reduction of IOP and the number of antiglaucomatous medications in cases with NVG in a 6-month follow-up period.     

Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy

Objective: To study the safety and efficacy of intravitreal injection of bevacizumab followed by aqueous shunting tube surgery for the management of neovascular glaucoma (NVG).Study Design: A prospective, non-randomized study with a historical control group.Participants: Twenty eyes of 20 patients with intractable NVG were treated with intravitreal injection of bevacizumab followed by aqueous shunting surgery (IVB group). A historical group of 10 NVG eyes treated with panretinal photocoagulation followed by aqueous shunting surgery without bevacizumab injection was used for comparison (PRP group).Methods: Injection of bevacizumab (1.25 mg/0.05 mL) was performed under topical anesthesia. An Ahmed valve was implanted in all cases after 1-2 weeks. In the IVB group, 10 eyes received postoperative panretinal photocoagulation (subgroup IA), and 10 eyes were followed without further photocoagulation (subgroup IB). Minimum follow-up was I year or when failure was diagnosed.Results: Mean preoperative intraocular pressure (IOP) was 46.5 mm Hg in the IVB group and 49.2 mm Hg in the PRP group (p = 0.5). After bevacizumab injection, iris neovessels regressed markedly. The final IOP after aqueous shunting tube surgery was 18.8 mm Hg in the IVB group and 15.9 mm Hg in the PRP group (p = 0.2). Postsurgical complications were comparable between the groups. The success rate was 85% and 70% in the 2 groups, respectively. Two eyes were considered failures, and 3 required repeated bevacizumab injections in subgroup IB as compared with I in subgroup IA.Conclusion: Intravitreal bevacizumab is a useful preparatory step to safely and effectively implant an aqueous shunting tube in NVG. Panretinal photocoagulation after bevacizumab injection promotes the success rate of aqueous shunt surgery by permanent ablation of the ischemic retina.     

Bevacizumab辅助治疗新生血管性青光眼

目的:观察玻璃体腔注射bevacizumab(intravitreal bevacizumab,IVB),联合玻璃体切除、视网膜光凝+小梁切除术治疗新生血管性青光眼(neovascular glaucoma,NVG)临床疗效。方法:对2007-06/2009-06在我院眼科收治由于视网膜中央静脉阻塞(缺血型)继发新生血管性青光眼患者27例27眼,角膜缘后3.5mm玻璃体腔注射bevacizumab0.05mL/1.25mg,治疗后7d进行玻璃体切除、视网膜光凝+小梁切除。术后随访12mo,观察视力、虹膜及房角新生血管及眼压情况。结果:IVB 7d后,25眼虹膜表面、房角新生血管消失(93%)。2眼新生血管明显变细,但未完全消退(7%)。IVB治疗前平均眼压(55.81±4.65)mmHg,治疗后7d平均眼压(42.07±7.49)mmHg,两者眼压比较虽然差异有显著性(t=14.973,P<0.01),但局部应用降眼压药后眼压仍高于正常范围(28～50)mmHg。玻璃体切除、视网膜光凝+小梁切除术后1,3,6,9,12mo,平均眼压分别为(14.85±4.56;16.70±3.73;20.04±6.58;19.30±4.74;19.67±4.12)mmHg,与IVB后7d平均眼压比较差异均有显著性(P<0.01)。手术后眼压控制完全成功22眼(82%),部分成功3眼(11%),眼压未控制2眼(7%)。27眼视力均保持稳定或稍有增进。结论:IVB辅助手术治疗NVG,可以促进虹膜、房角、视网膜新生血管迅速消退,有效的控制眼压,降低手术并发症,提高了手术的成功率,同时进行原发病的治疗远期效果明显提高。     

虹膜光凝联合复合式小梁切除治疗新生血管性青光眼

目的评价倍频532激光虹膜表面新生血管光凝术联合复合式小梁切除术治疗新生血管性青光眼的效果。方法对31例（32只眼）新生血管性青光眼先用倍频532 nm激光封闭虹膜表面新生血管,1～d天后再行复合式小梁切除术。结果术后随访半年,27例（28只眼）眼压控制在21 mm Hg以下,有效率达85.71%。结论倍频532激光虹膜光凝联合复合式小梁切除术是治疗新生血管性青光眼较为满意的方法。     

玻璃体腔注射雷珠单抗联合小梁切除术及PRP治疗新生血管性青光眼

目的：观察玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝(panretinal photocoagulation, PRP)治疗新生血管性青光眼(NVG)的中期临床疗效。

方法：回顾分析我院2015-01/2017-03间收治的21例21眼新生血管性青光眼病例的临床资料,治疗上均先行玻璃体腔雷珠单抗注射,后行5-氟尿嘧啶联合下的小梁切除术及术后行全视网膜光凝。随访6mo观察治疗前后患者眼内压(intraocular pressure,IOP)、视力、虹膜及房角新生血管、抗青光眼药物的应用、术后的并发症等。

结果：患者随访至少6mo。21例患者术后眼压均得到了有效控制,患者术前平均眼压为53.17±10.52mmHg,术后6mo复查平均眼压为18.50±3.51mmHg,与术前眼压比较,差异有统计学意义(P=0.001)。术后视力均有一定程度提高。3眼出现前房出血及玻璃体出血情况,予保守治疗后消退。患者虹膜及房角新生血管明显消退。

结论：玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的中期疗效稳定。     

Intracameral anti-VEGF injection for advanced neovascular glaucoma after vitrectomy with silicone oil tamponade

AIM: To evaluate the effect of intracameral injection of conbercept for the treatment of advanced neovascular glaucoma(NVG) after vitrectomy with silicone oil tamponade.METHODS: Conbercept 0.5 mg/0.05 m L was injected into the anterior chamber of 5 eyes, which had developed advanced NVG after vitrectomy with silicone oil tamponade. Then, trabeculectomy with mitomycin C and pan-retinal photocoagulation(PRP) or extra-PRP were conducted within 2 d. The follow-up time was 6 mo. Best-corrected visual acuity(BCVA), intraocular pressure(IOP), neovascularization of iris(NVI) were recorded before and after treatment.RESULTS: Within 2 d after injection, IOP control, and NVI regression were optimal for trabeculectomy. Hyphema occurred in one eye in the process of injection. But none of them present hyphema after trabeculectomy. At the end of follow-up time, all eyes had improved BCVA, well-controlled IOP, and completely regressed NVI. CONCLUSION: Intracameral injection of conbercept is safe and effective in the treatment of patients with advanced NVG after vitrectomy with silicone oil tamponade. Within 2 d after injection is the optimal time window for trabeculectomy, which can maximally reduce the risk of perioperative hyphema.     

不同方法联合治疗新生血管性青光眼的临床观察

目的:观察不同方法[降眼压药物+玻璃体腔注射雷珠单抗+复合式小梁切除+ 全视网膜光凝(PRP)]联合治疗新生血管性青光眼(neovascular glaucoma,NVG)的疗效.方法:回顾性非随机临床对照研究.新生血管性青光眼患者24例24眼纳入研究,经降眼压药物治疗后,7眼正常眼压,17眼高眼压.所有患者均行玻璃体腔注射雷珠单抗 0.50mg/0.05mL,7d后行复合式小梁切除术.复合式小梁切除术后予以全视网膜光凝.术后随访6~18mo,观察联合治疗后虹膜新生血管消退时间、眼压、视力变化,术中术后并发症以及滤过泡情况.结果:所有患者玻璃体腔注射雷珠单抗后,虹膜新生血管1wk内完全消退.治疗前平均眼压41.38±3.16mmHg,治疗后6mo平均眼压12.69±1.52mmHg,两者比较有统计学差异(F=25.592,P<0.05).治疗前最佳矫正视力>0.1者3眼,视力0.01~0.1者10眼,无光感~指数者11眼,治疗后最佳矫正视力>0.1者5眼,视力0.01~0.1者16眼,无光感~指数者3眼,差异有统计学意义(Z=-2.201,P<0.05) .结论:不同方法联合治疗NVG患者能有效地控制眼压,保护视功能.     

综合治疗新生血管性青光眼的疗效观察

目的：评价玻璃体腔雷珠单抗注射联合全视网膜激光光凝（ panretinal photocoagulation ,PPR）及复合小梁切除术治疗新生血管性青光眼的临床疗效。方法：收集我院2015－01／11确诊为新生血管性青光眼患者14例14眼,依次行玻璃体腔雷珠单抗注射、PPR及复合小梁切除术治疗。观察术后眼压、视力、虹膜新生血管及术中术后并发症的情况。结果：经3～6mo观察及随访,末次随访平均眼压为18．00±6．70mmHg,较术前平均眼压（41．65±4．07mmHg）有显著降低（ t＝11．288,P＜0．05）。手术成功定义为未辅助用降眼压药物,眼压＜21 mmHg;有效定义为辅助用降眼压药物,眼压＜21mmHg。末次随访11眼眼压＜21mmHg,成功率为79％;2眼有效（14％）;1眼失败,眼压失控后行睫状体冷冻治疗。视力检查结果显示6眼稍有提高,7眼不变,1眼减退;13眼虹膜新生血管消失,1眼在随访的第3 mo消失的虹膜新生血管又复现,给予再次玻璃体腔雷珠单抗注射并补充眼底视网膜激光治疗后消失;术后前房积血1眼,1 wk后吸收,未出现术后浅前房及眼球萎缩患者。结论：玻璃体腔雷珠单抗注射及复合小梁切除术联合PPR治疗新生血管性青光眼安全、可靠,疗效确定。     

小梁切除联合羊膜植入治疗新生血管性青光眼的疗效

目的: 评价小梁切除术联合羊膜植入治疗新生血管性青光眼(neovascular glaucoma,NVG)的临床疗效。方法: 回顾42例42眼小梁切除联合羊膜植入治疗NVG的患者。观察术后视力、眼压、前房深度、出血、虹膜新生血管及滤过情况。结果: 术后6～12mo,34例眼压控制在21mmHg以下,6例症状缓解,加用盐酸卡替洛尔滴眼液治疗后眼压控制在21mmHg以下。结论: 小梁切除联合羊膜植入治疗NVG疗效理想。     

四联手术治疗新生血管性青光眼

目的:评价小梁切除术+丝裂霉素C(mitomycin C,MMC)联合玻璃体腔注射曲安奈德(triamcinolone acetonide,TA)睫状体冷冻术治疗新生血管性青光眼(neovascular glaucoma,NVG)的效果。方法:对16例16眼NVG行小梁切除术+MMC,玻璃体腔注射TA混悬液4mg/0.1mL,睫状体冷冻180°范围4～6个点,每点冷冻时间60s。结果:眼压控制正常者14眼(88%),其余2眼眼压仍高出正常范围,但眼痛症状明显缓解。虹膜新生血管大部分消退14眼,部分消退2眼,无眼球萎缩病例。结论:小梁切除术+MMC联合玻璃体腔注射TA睫状体冷冻术是治疗NVG一种有效方法。     

Ahmed引流阀植入联合玻璃体腔注射Bevacizumab治疗NVG

目的：观察Ahmed引流阀植入联合玻璃体腔注射bevacizumab(贝伐珠单抗)治疗新生血管性青光眼(neovascular glaucoma,NVG)的疗效。

方法：对22例22眼新生血管性青光眼患者先进行玻璃体腔注射bevacizumab 0.1mL(2.5mg),待虹膜新生血管消退后行Ahmed青光眼阀门植入术。术后观察视力、眼压、虹膜新生血管消退情况、术中及术后并发症,随访6～36(平均24)mo。

结果：玻璃体腔注药后1wk内22眼虹膜新生血管均有不同程度消退,Ahmed引流阀植入术后随访22眼中仅有3眼联合使用1～3种抗青光眼药物,眼压控制在21mmHg之内,1眼因眼压失控而行睫状体光凝术(810激光),其余18眼均无需加用抗青光眼药物眼压控制在正常范围内,最后一次随访,平均眼压15.59±3.21mmHg,与术前平均眼压(45.36±8.13mmHg)相比,差异有统计学意义(P<0.05)。视力提高者9眼(41%),保持术前视力者13眼。全部病例在玻璃体腔注射bevacizumab及Ahmed引流阀植入术中术后均未观察到严重手术并发症。

结论：Ahmed引流阀植入联合玻璃体腔注射bevacizumab治疗NVG安全有效,手术成功率高,并发症少,有利于保护残留视功能。     

Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma

Background Treatment of neovascular glaucoma (NVG) must be focused on the reduction of intraocular pressure (IOP) and prompt application of pan retinal photocoagulation (PRP). A combination of complete PRP during vitrectomy with trabeculectomy should theoretically be a better method to lower the IOP rapidly in eyes with NVG. The purpose of our study is to assess the efficacy of combining pars plana vitrectomy and PRP with trabeculectomy assisted by mitomycin C (MMC) on NVG eyes secondary to diabetic retinopathy.Methods Twenty-five eyes with NVG associated with diabetic retinopathy had pars plana vitrectomy, followed by PRP and trabeculectomy with MMC. The eyes were divided into two groups: nine eyes with vitreous hemorrhage, fibrovascular membrane and/or retinal detachment were placed in the Proliferation group; and 16 eyes without vitreous hemorrhage, fibrovascular membrane, or retinal detachment were placed in the PC (photocoagulation) group. These eyes had vitrectomy performed so that PRP could be safely performed from ora to ora. The surgical outcome in the two groups was assessed by Kaplan-Meier survival analysis. The criteria for success were a postoperative intraocular pressure (IOP) ≤21 mmHg and a preservation of light perception.Results In the Proliferation group, Kaplan-Meier life-table analysis showed that the success rate was 55.6% after 1 year and 18.5% after 2 years. The success rate in the PC group was 81.2% from 1 to 3 years after surgery. The surgical outcome was significantly better in the PC group than in the Proliferation group (P=0.009). In the Proliferation group, four eyes had preoperative vitreous hemorrhage, three eyes had a fibrovascular membrane, and two eyes had a retinal detachment. Three of four eyes with vitreous hemorrhage achieved good IOP control. On the other hand, the IOP of all eyes with retinal detachment and fibrovascular membrane were not lowered significantly.Conclusions Complete PRP combined with trabeculectomy with MMC can effectively reduce the elevated IOP in eyes with NVG. However, this combined treatment is not effective in eyes with proliferative membranes and retinal detachments.     

新生血管性青光眼治疗时机的临床研究

目的:探讨新生血管性青光眼(neovascular glaucoma,NVG)发病不同时期治疗方案的选择。方法:对116例123眼被诊断为NVG患者的病历资料,按照CNV的不同分期进行回顾性总结。结果:NVGⅠ期患者17眼行全视网膜光凝,16眼新生血管消退。Ⅱ期57眼中,17眼行全视网膜光凝,新生血管消退。26眼行全视网膜光凝联合小梁切除术,23眼眼压控制良好。9眼行玻璃体切除+全视网膜光凝联合小梁切除术,8眼眼压控制良好。5眼行青光眼阀植入术联合全视网膜光凝术,眼压控制良好。Ⅲ期49眼中,3眼行青光眼阀植入术联合全视网膜光凝术,2眼眼压控制良好。38眼行周边视网膜冷凝、睫状体冷冻联合小梁切除术,29眼眼压控制良好。3眼行眼球摘除术,5眼行睫状神经剪断术。结论:从NVG分期角度出发,应根据患者不同病情制订个体化的治疗方案。